<DOC>
	<DOCNO>NCT00162526</DOCNO>
	<brief_summary>The present protocol attempt prevent/treat mucositis highly susceptible patient subject maximally tolerated dos subsequently-myeloablative myeloablative dos chemoradiotherapy support autologous allogeneic stem cell transplantation Department Bone Marrow Transplantation . Mucositis major problem management transplant recipient subject patient risk sepsis , need parenteral nutrition need narcotic . We plan 2 arm study , compare 2 safe vitamin E base formulation placebo .</brief_summary>
	<brief_title>Tocopherol Novel Treatment Cancer Related Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Males nonpregnant nonlactating female , 18 year age old time screening , receive myeloablative agonist without total body irradiation ( TBI ) preparation either allogeneic autologous HSCT . Patients hospitalize expect remain hospitalized marrow recovery . Karnofsky performance status 60 great ECOG performance status 2 less . Normal dental examination assess investigator . Clinically significant acute active oral cavity infection . Patients take investigational nonapproved oral therapy oral mucositis . Known hypersensitivity Vitamin E .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>